Analyst Conference Summary

conference date: May 6, 2021 @ 5:30 AM Pacific Time
for quarter ending: March 31, 2021 (Q1, first quarter)

Forward-looking statements

Overview: Continues to prepare for bardoxolone possible FDA approval.

Basic data (GAAP):

Revenue was $0.9 million, down sequentially from $3.1 million and down from $1.3 million in the year-earlier quarter.

Net income was negative $67 million, down sequentially from negative $66 million, and down from negative $49 million year-earlier.

Diluted EPS was negative $1.86, up sequentially from negative $1.90, and up from negative $1.47 year-earlier. (on higher share count)

Guidance:

Believes cash is sufficient to fund operations through mid 2024.

Conference Highlights:

Warren Huff, CEO said "We made significant progress during the first quarter of 2021 with the submission of our NDA for bardoxolone for the treatment of CKD caused by Alport syndrome coming less than four months after reporting positive results from Year 2 of our Phase 3 Cardinal trial. Alport syndrome is a devastating disease that affects 30,000 to 60,000 patients in the United States. We are pleased with the FDA's recent decision to accept our application for filing and look forward to continuing to work with the FDA during its review of our application."

In April 2021 the FDA accepted the NDA for bardoxolone, setting a PDUFA date of February 25, 2022. On March 1, 2021 Reata had submitted the New Drug Application to the FDA for Bardoxolone in Alport Syndrome. The Phase 3 CARDINAL trial of bardoxolone methyl for CKD (chronic kidney disease) caused by Alport Syndrome reported positive topline 2-year data in Q4 2020.The study showed that improved kidney function continued in the third year of treatment, and the largest treatment effect was observed in pediatric patients. Reata is actively preparing commercial teams for bardoxolone. An Advisory Committee hearing is anticipated.

Reata is planning to amend the FALCON protocol to increase the target enrollment from 300 patients to a total of 550 patients and expects to complete enrollment by the end of 2021. This is for Bardoxolone in Autosomal Dominant Polycystic Kidney Disease (ADPKD). As of Feb. 2021 over 220 patients had been enrolled. Each patient is followed for 2 years.

An investigator initiated trial of Bardoxolone for kidney-related effects of Covid-19 began in Q1 2021.

The Phase 2 BARCONA IST study of bardoxolone in patients with COVID-19 is enrolling. It is a randomized, double-blind trial that will enroll approximately 40 patients with a primary endpoint of safety and treatment duration of up to 29 days in hospitalized patients.

The MERLIN Phase 2 study of bardoxolone in CKD with risk for rapid progression began in February 2021 with data expected before the end of 2021.

A Phase 2 study PHOENIX of bardoxolone methyl for CKD from four rare causes produced clinically and statistically significant results in Q1 2019. Reata also plans to pursue IgAN, T1D CKD, and FSGS as commercial indications for bardoxolone

CATALYST Phase 3 topline data for bardoxolone for CTD-PAH (connective tissue disease associated pulmonary arterial hypertension) was expected in the first half of 2020. However, for safety the trial was stopped during the pandemic (as of May 11, 2020). Primary endpoint is 6-minute walk distance. Enrollment was completed in 2019.

A type C meeting will be held with the FDA in Q2 2021. In November 2020, the FDA suggested additional exploratory analyses that could inform the future development program of omaveloxolone in patients with FA (Friedreich's Ataxia). In Q4 2020 the Baseline-Controlled Study of Omaveloxolone for Friedreich's Ataxia met its primary endpoint of paired difference in annualized mFARS slope with a statistically significant 3.76 point improvement (p=0.0022) between the treatment and pre-treatment periods in the primary analysis population. Further, all sensitivity analyses of the primary analysis showed a significant treatment effect. Thus, we believe that the results of the Baseline-Controlled Study support the positive mFARS results of Part 2 and provide additional evidence of the effectiveness of omaveloxolone in FA. The Baseline-Controlled Study completed in October 2020 and the results were provided to the FDA. The FDA confirmed that it will review the study results and may request a meeting with us to discuss the conclusions of its review. If the FDA views these results as sufficient to increase the persuasiveness of data from Part 2, our plan would be to submit an NDA in mid-2021. However, there can be no assurance that the FDA will accept the design of the BaselineControlled Study. Previously, the FDA was not convinced that the MOXIe Part 2 results would support a single study approval without additional evidence that lends persuasiveness to the results. The FDA stated that we will need to conduct a second pivotal trial that confirms the mFARS results of the MOXIe Part 2 study with a similar magnitude of effect. Our counterproposal was for the crossover study.

Completed a Phase 1 study of RTA 901 for Diabetic Peripheral Neuropathic Pain (DPNP) with positive results in Q1 2021. Plans both an additional Phase 1 study in Q2 2021 and a Phase 2 study in Q4 2021.

Cash ended at $778 million, down sequentially from $818 million. No debt.

Non-GAAP numbers: net income negative $42 million, up sequentially from negative $43 million and down from negative $30 million year-earlier. Diluted EPS negative $1.16 up sequentially from negative $1.25 and down from negative $0.89 year-earlier.

Operating expense of $56 million consisted of $35 million for R&D, $21 million for general and administrative, and depreciation of $0 million. Other expense net $13 million. Income tax benefit $0 million.

Q&A summary:

Ad Com preparation, issues? Known issues, a new entity with a novel mechanism of action. Treatment of secondary analyses.

We believe we were not given priority review because of its novelty and presentation of new issues.

Omav type C meeting scenarios? FDA has requested additional evidence of persuasiveness. We have generated analyses for that. When next steps are clear, we will communicate them.

Friedreich's Ataxia in EU? We are seeking guidance from the EMA to incorporate into the development program.

Diabetic CKD in Japan, could that be used in US? Not likely, those trials are overseen by an independent data monitoring board. Our own data is a large set and should be sufficient.

The FDA gave us the design for the bardoxalone trial, we executed it as guided, we think issues other companies have had should not be a problem for us.

OpenIcon Analyst Conference Summaries Main Page

Search

More Analyst Conference Pages: